Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)

Assessment Status Assessment process complete
HTA ID -
Drug Paritaprevir boosted with ritonavir and ombitasvir with or without dasabuvir
Brand (Vierkirax®)/(Exviera®)
Indication Exviera® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults. Exviera® must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera® combination therapy are viekirax® or viekirax® and ribavirin. Viekirax® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults viekirax® must not be administered as monotherapy. Depending on the patient population, the recommended co-administered medicinal products for viekirax® are exviera® or exviera® and ribavirin or ribavirin.
Assessment Process
Rapid review commissioned 21/12/2014
Rapid review completed 13/01/2015
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 15/01/2015
NCPE assessment completed 10/02/2016
NCPE assessment outcome Reimbursement recommended in certain sub-populations of patients with genotype 1 & 4